MedTrace Logo

A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)

NCT04229706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-09-05

No results posted yet for this study

Summary

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in Hyperplastic disease of breast patients .

Conditions

  • Hyperplasia of Breast

Interventions

DRUG

High dose Xiang Ju Ru Pi Ning capsule

xingjurupining capsule,8 capsule,tid,3 months.

DRUG

Low dose Xiang Ju Ru Pi Ning capsule

xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.

DRUG

Xiang Ju Ru Pi Ning capsule placebo

xiangjurupining capsule,8 capsule,tid,3 months.

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2022-01-12
Completion
2022-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229706 on ClinicalTrials.gov